Neste fase
Når kommer nyheter knyttet til Pcib?. Samarbeid , partneravtaler eller oppkjøp?
Redigert 10.04.2021 kl 16:20
Du må logge inn for å svare
fabian2
11.04.2021 kl 13:22
2970
Den eiendommelige interessen for PCIB - også fra de negative og sjikanerende - skyldes hovedsakelig en ting : Hvis det løsner (avtalemessig )så løsner det så voldsomt. I mellomtiden kan man spøke og latterliggjøre.----Moderen PHO er i 140 nå. En stund var mor og datter på samme pris. Det samme kan skje om igjen. Derfor eiendommelig interesse for en midlertidig kurs-taper. Alle som følger med , vet at "vi" venter på en avtale , spørsmålet er NÅR den kommer. For PHO kom den som lyn fra klar himmel. Særdeles sannsynlig skjer det samme for PCIB. Jeg regner med i år 2021. Og da kan kursen gå høyt over 80-tallet som man tidligere var på. Derfor interessen.
Redigert 11.04.2021 kl 13:47
Du må logge inn for å svare
bravi
11.04.2021 kl 14:42
2904
Greit å være realistisk i dette caset, men man vet aldri med slike selskaper. At Pcib er et evighets case vet de fleste, sannsynligvis er det første av kursmessig betydning som kommer en melding om positive resultater av en eller annen test etterfulgt av en melding om emisjon, slik vi har sett det tidligere. Da er spørsmålet til hvilken kurs?
Kommer det bare melding om emisjon vil det være helt tragisk for kursen.
Kommer det bare melding om emisjon vil det være helt tragisk for kursen.
Redigert 11.04.2021 kl 15:01
Du må logge inn for å svare
sokaratest
11.04.2021 kl 15:14
2872
kan Meget fort bli en vinner. Historien viser store og raske utslag.
heilo888
11.04.2021 kl 17:56
2746
Unik teknologi, men tragisk ledelse som ikke klarer å kapitalisere på den!
Nå er det langt på overtid at PW. og ledelsen tar av seg de hvite forskerfrakkene og tar blådressene på slik at man får kommersialisert noe av forskningen!
PCIB hadde sårt trengt en mer fremoverlent og internasjonal dynamisk kapasitet som CEO!!!!
Nå er det langt på overtid at PW. og ledelsen tar av seg de hvite forskerfrakkene og tar blådressene på slik at man får kommersialisert noe av forskningen!
PCIB hadde sårt trengt en mer fremoverlent og internasjonal dynamisk kapasitet som CEO!!!!
Redigert 11.04.2021 kl 20:15
Du må logge inn for å svare
fabian2
01.05.2021 kl 15:46
2101
sokaratest skrev kan Meget fort bli en vinner. Historien viser store og raske utslag.
Unik teknologi vil trumfe alt , og les nå børsmeldingen fra fredag kveld om at USA har startet. Så da starter nok mer intensiv baissing.
Redigert 01.05.2021 kl 15:47
Du må logge inn for å svare
sokaratest
01.05.2021 kl 18:00
1997
Kan bli en flott uke for Pcib aksjonærer - påtide med en kraftig opptur
Panis
05.05.2021 kl 11:06
1249
Suwon, South Korea and Oslo, Norway, May, 5th 2021 – OliX Pharmaceuticals Inc. (KOSDAQ: 226950) a leading developer of RNAi therapeutics, and PCI Biotech (OSE: PCIB), a cancer focused biopharmaceutical company with a unique intracellular delivery technology, today announced an extensive research collaboration. OliX Pharmaceuticals and PCI Biotech will combine their know-how and technology platforms to explore synergies and further partnership on dermatology and other applications.
The partnership is governed by a research collaboration agreement, under which the collaborators will perform an extensive evaluation of technology compatibility and synergy based on OLX104C (Androgenic Alopecia) preclinical studies. The companies will evaluate results achieved from this research collaboration to explore the potential for further development and partnership.
Commenting on the announcement, Dong Ki Lee, CEO of OliX Pharmaceuticals said: “We are very excited to collaborate with PCI Biotech. Combining our proprietary asiRNA platform with PCI’s leading fimaNAc delivery technology will significantly accelerate our efforts to bring our dermatological RNAi programs to the clinic. We also expect to expand the area of application to our cancer immunotherapy pipeline and mRNA vaccines developed by our subsidiary, mCureX, in the near future.”
PCI Biotech’s CEO, Per Walday, added: “We are very pleased to initiate this exciting collaboration with OliX Pharmaceuticals. This collaboration builds on the strong potential of our intracellular delivery platform technology for nucleic acid based therapies, within a therapeutic field of good technological fit. Combining the leading technologies of OliX Pharmaceuticals and PCI Biotech may lead to new promising applications and we look forward to the collaboration.”
About OliX Pharmaceuticals
OliX Pharmaceuticals is a clinical stage pharmaceutical company developing therapeutics against a variety of disorders by down-regulating expression of disease-causing genes, based on its own proprietary RNAi technology. The Company’s core RNAi platform, asymmetric siRNA (asiRNA), is a unique gene silencing technology based on RNA interference (RNAi), which is considered as the most efficient gene silencing technology. Based on asiRNA technology, OliX has developed cell penetrating asiRNA (cp-asiRNA), a therapeutic RNAi platform to effectively target locally administrable diseases, such as hypertrophic scar, dry and wet age-related macular degeneration (AMD), subretinal fibrosis, idiopathic pulmonary fibrosis (IPF), and neuropathic pain. OliX has also developed another therapeutic RNAi platform, GalNAc-asiRNA, to target a variety of liver diseases. For more information, please visit: https://www.olixpharma.com
About PCI Biotech
PCI Biotech is a biopharmaceutical late stage clinical development company focusing on development and commercialization of novel therapies for the treatment of cancer through its innovative photochemical internalization (PCI) technology platform, for intracellular delivery. PCI induces triggered endosomal release that enables drugs to reach intracellular therapeutic targets. Currently, PCI Biotech is working on three programs: fimaChem (enhancement of chemotherapeutics for localized treatment of cancer), fimaVacc (T-cell induction technology for therapeutic vaccination), and fimaNAc (nucleic acid therapeutics delivery). For more information, please visit: www.pcibiotech.com
The partnership is governed by a research collaboration agreement, under which the collaborators will perform an extensive evaluation of technology compatibility and synergy based on OLX104C (Androgenic Alopecia) preclinical studies. The companies will evaluate results achieved from this research collaboration to explore the potential for further development and partnership.
Commenting on the announcement, Dong Ki Lee, CEO of OliX Pharmaceuticals said: “We are very excited to collaborate with PCI Biotech. Combining our proprietary asiRNA platform with PCI’s leading fimaNAc delivery technology will significantly accelerate our efforts to bring our dermatological RNAi programs to the clinic. We also expect to expand the area of application to our cancer immunotherapy pipeline and mRNA vaccines developed by our subsidiary, mCureX, in the near future.”
PCI Biotech’s CEO, Per Walday, added: “We are very pleased to initiate this exciting collaboration with OliX Pharmaceuticals. This collaboration builds on the strong potential of our intracellular delivery platform technology for nucleic acid based therapies, within a therapeutic field of good technological fit. Combining the leading technologies of OliX Pharmaceuticals and PCI Biotech may lead to new promising applications and we look forward to the collaboration.”
About OliX Pharmaceuticals
OliX Pharmaceuticals is a clinical stage pharmaceutical company developing therapeutics against a variety of disorders by down-regulating expression of disease-causing genes, based on its own proprietary RNAi technology. The Company’s core RNAi platform, asymmetric siRNA (asiRNA), is a unique gene silencing technology based on RNA interference (RNAi), which is considered as the most efficient gene silencing technology. Based on asiRNA technology, OliX has developed cell penetrating asiRNA (cp-asiRNA), a therapeutic RNAi platform to effectively target locally administrable diseases, such as hypertrophic scar, dry and wet age-related macular degeneration (AMD), subretinal fibrosis, idiopathic pulmonary fibrosis (IPF), and neuropathic pain. OliX has also developed another therapeutic RNAi platform, GalNAc-asiRNA, to target a variety of liver diseases. For more information, please visit: https://www.olixpharma.com
About PCI Biotech
PCI Biotech is a biopharmaceutical late stage clinical development company focusing on development and commercialization of novel therapies for the treatment of cancer through its innovative photochemical internalization (PCI) technology platform, for intracellular delivery. PCI induces triggered endosomal release that enables drugs to reach intracellular therapeutic targets. Currently, PCI Biotech is working on three programs: fimaChem (enhancement of chemotherapeutics for localized treatment of cancer), fimaVacc (T-cell induction technology for therapeutic vaccination), and fimaNAc (nucleic acid therapeutics delivery). For more information, please visit: www.pcibiotech.com